Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY) and Medtronic (MDT).
Alnylam Pharma (ALNY)
Morgan Stanley analyst David Lebovitz maintained a Buy rating on Alnylam Pharma today and set a price target of $203.00. The company’s shares closed last Wednesday at $124.15.
According to TipRanks.com, Lebovitz is a 3-star analyst with an average return of 4.1% and a 53.7% success rate. Lebovitz covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Syndax Pharmaceuticals, and Ionis Pharmaceuticals.
Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $165.31, which is a 29.7% upside from current levels. In a report released yesterday, Needham also assigned a Buy rating to the stock with a $160.00 price target.
See today’s analyst top recommended stocks >>
Medtronic (MDT)
Morgan Stanley analyst David Lewis maintained a Hold rating on Medtronic today and set a price target of $120.00. The company’s shares closed last Wednesday at $112.96.
According to TipRanks.com, Lewis is a 5-star analyst with an average return of 16.2% and a 71.5% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Baxter International, and Irhythm Technologies.
Medtronic has an analyst consensus of Strong Buy, with a price target consensus of $125.80, representing a 10.6% upside. In a report released today, Leerink Partners also maintained a Hold rating on the stock with a $123.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MDT:
